AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

RECCE PHARMACEUTICALS LTD

0.290

+0.000

Volume:92.67K

Turnover:26.75K

Market Cap:72.42M

PE:-3.16

High:0.290

Open:0.285

Low:0.280

Close:0.290

Loading ...

Overview Company News Filings

BRIEF-Recce Pharmaceuticals Receives Approval For Additional Phase II Trial Of RECCE® 327 Topical Gel For Diabetic Foot Infections

Recce Pharmaceuticals Receives Approval for Additional Phase Ii Trial of Recce® 327 Topical Gel for Diabetic Foot Infections

THOMSON REUTERS

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Recce Receives Ethics Committee Nod to Allow Patients Access to Topical Gel Treatment

MT Newswires Live

Recce Pharmaceuticals Ltd-Entitlement Offer - Offer Booklet and Access Letter

THOMSON REUTERS

Recce Pharmaceuticals Ltd - Proceeds to Support Phase Iii Trials for Diabetic Foot Infections in Indonesia and Australia

THOMSON REUTERS

Recce to raise $15.8M in Placement and Entitlement Offer to fund trials

The Market Herald

BUZZ-Australia's Recce Pharmaceuticals slumps to five-year low on discounted placement

BRIEF-Recce Pharmaceuticals Announces Placement And Entitlement Offer

Recce Pharmaceuticals Ltd-Cleansing Notice - Entitlement Offer

THOMSON REUTERS

Recce Pharmaceuticals Ltd-Placement and Entitlement Offer to Fund Phase Iii Trials

THOMSON REUTERS

Recce Pharmaceuticals Ltd - Placement at a$0.28 per New Share

THOMSON REUTERS

Further weakness as Recce Pharmaceuticals (ASX:RCE) drops 12% this week, taking three-year losses to 58%

Simply Wall St.

BUZZ-Australia's Recce Pharmaceuticals falls on widened loss

BRIEF-Recce Pharmaceuticals Says HY Net Loss For Period Attributable A$7.7 Million

BRIEF-Recce Pharmaceuticals Says Japan Patent Allowance For Recce Anti-Infectives

Recce Pharmaceuticals Obtains Japan Patent for Anti-Infectives

MT Newswires Live

Recce Pharmaceuticals Ltd - Japan Patent Allowance for Recce Anti-Infectives

THOMSON REUTERS

BRIEF-Recce Pharmaceuticals Reports Positive Data From Phase Ii Trial Of Recce® 327 Gel In Acute Bacterial Skin And Skin Structure Infections, Supporting Accelerated Commercialization Pathway

Recce Pharmaceuticals Ltd - R327g Achieves 93% Primary Efficacy Endpoint in 14 Days

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RCE.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RCE.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","market":"AU","secType":"STK","nameCN":"RECCE PHARMACEUTICALS LTD","latestPrice":0.29,"timestamp":1745475120000,"preClose":0.29,"halted":0,"volume":92674,"delay":0,"nameEN":"RECCE PHARMACEUTICALS LTD","floatShares":167272518,"shares":249728760,"eps":-0.091765,"marketStatus":"Market Closed","change":0,"latestTime":"04-24 16:12:00 AEST","open":0.285,"high":0.29,"low":0.28,"amount":26745,"amplitude":0.034483,"askPrice":0.29,"askSize":63653,"bidPrice":0.28,"bidSize":131092,"shortable":3,"etf":0,"ttmEps":-0.091765,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745798400000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.29,"openAndCloseTimeList":[[1745452800000,1745474400000]],"volumeRatio":0.5204539043732951,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","floatShares":167272518,"roa":"-217.58%","roe":"-1277.62%","lyrEps":-0.099727,"volumeRatio":0.5204539043732951,"shares":249728760,"dividePrice":0,"high":0.29,"amplitude":0.034483,"preClose":0.29,"low":0.28,"week52Low":0.275,"pbRate":"-14.52","psRate":"7.55","week52High":0.688,"institutionHeld":0,"latestPrice":0.29,"committee":0.346294,"eps":-0.091765,"divideRate":0,"volume":92674,"delay":0,"ttmEps":-0.091765,"open":0.285,"prevYearClose":0.48,"prevWeekClose":0.29,"prevMonthClose":0.357,"prevQuarterClose":0.357,"fiveDayClose":0.29,"twentyDayClose":0.362,"sixtyDayClose":0.461},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCE.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529507322","title":"BRIEF-Recce Pharmaceuticals Receives Approval For Additional Phase II Trial Of RECCE® 327 Topical Gel For Diabetic Foot Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2529507322","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529507322?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:20","pubTimestamp":1745410832,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Receives Approval For Additional Phase II Trial Of RECCE 327 Topical Gel For Diabetic Foot InfectionsApril 23 (Reuters) - Recce Pharmaceuticals Ltd RCE.AX:RECCE PHARMACEUTI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA4VRNXJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2529050466","title":"Recce Pharmaceuticals Receives Approval for Additional Phase Ii Trial of Recce® 327 Topical Gel for Diabetic Foot Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2529050466","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529050466?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:00","pubTimestamp":1745409600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA4VRNXJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2529507878","title":"Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2529507878","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529507878?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:00","pubTimestamp":1745409600,"startTime":"0","endTime":"0","summary":"Human Research Ethics Committee  approval received to allow up to 20 additional patients access to RECCE 327 Topical Gel  treatment under existing open-label study protocol. Program enables access to R327G for diabetic foot infections , following recent positive Phase II results in acute bacterial skin and skin-structure infections , including diabetic foot ulcers . Access focused on patients with DFU infections given the unmet medical need, as ~40% experience ulcer recurrence within a year of healing. The study will start now, running in parallel to Registrational Phase 3 in Indonesia for DFI and planned Registrational Phase 3 for ABSSSI in Australia, on track for H2 2025. The study will start now and run in parallel with Recce’s Indonesian Phase 3 trial, which remains on track to commence shortly. This program does not impact the initiation timeline of the Registrational Phase 3 DFI study in Indonesia or the planned Registrational Phase 3 ABSSSI study in Australia. The study is desig","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/recce-pharmaceuticals-receives-approval-additional-120000639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU0345780281.USD","LU0498741890.SGD","LU0724618789.USD","BK4017","LU0368265764.SGD","XKO.AU","LU1223082519.USD","BK4570","RCE.AU","XJO.AU","BK4588","BK4135","BK7096","BK4585","BK4522","LU1223082196.USD","BK4533","LU0055631609.USD","LU0496367417.USD","XAO.AU","LU0345780521.USD","GAIN","AU","LU0498741114.HKD","LU0788108826.HKD","LU1223083913.SGD","USA"],"gpt_icon":0},{"id":"2529315161","title":"Recce Receives Ethics Committee Nod to Allow Patients Access to Topical Gel Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2529315161","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529315161?lang=en_us&edition=fundamental","pubTime":"2025-04-22 13:26","pubTimestamp":1745299604,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  has secured human research ethics committee approval to allow up to 20 additional patients in its phase two clinical study to access Recce 327, a topical gel designed for diabetic foot infections , according to a Tuesday filing with the Australian bourse.The study will run concurrently with Recce's phase three trial in Indonesia, which is expected to deliver results later in the year, with regulatory approval and commercial launch anticipated in the first half of 2026, the filing said.Both studies aim to generate additional data to support future regulatory submissions, the filing added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2529368447","title":"Recce Pharmaceuticals Ltd-Entitlement Offer - Offer Booklet and Access Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2529368447","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529368447?lang=en_us&edition=fundamental","pubTime":"2025-04-22 08:07","pubTimestamp":1745280471,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUE52RNWQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2526563128","title":"Recce Pharmaceuticals Ltd - Proceeds to Support Phase Iii Trials for Diabetic Foot Infections in Indonesia and Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2526563128","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526563128?lang=en_us&edition=fundamental","pubTime":"2025-04-10 20:00","pubTimestamp":1744286403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUA7PSYQL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2526665377","title":"Recce to raise $15.8M in Placement and Entitlement Offer to fund trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2526665377","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526665377?lang=en_us&edition=fundamental","pubTime":"2025-04-10 11:17","pubTimestamp":1744255020,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals Ltd  is aiming to complete a capital raising of $15.8 million to funds its clinical trials in Indonesia and Australia through a $5M Placement to a private investor and $10.8M Entitlement Offer to shareholders.The Placement involves a commitment from a private investor based in Australia, and the issue of around 17.9M new fully paid ordinary Recce shares priced at 28 cents each, for a total of $5M.Alongside this, the company has launched an Entitlement Offer of 1 new share for every 6 existing fully paid ordinary Recce shares held by eligible shareholders, with the price being the same as the placement, and with the goal of raising $10.8M.Recce plans to use the Placement funds to drive completion of 1 of its Phase III topical clinical tests, while funds from the Entitlement offer will go towards the progression of other development programs.Join the discussion:See whatHotCopperusers are saying aboutRecce and be part of the conversations that move the markets.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/recce-to-raise-15-8m-in-placement-and-entitlement-offer-to-fund-trials-2025-04-10/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7096","XKO.AU","RCE.AU","XAO.AU","XJO.AU"],"gpt_icon":0},{"id":"2526785063","title":"BUZZ-Australia's Recce Pharmaceuticals slumps to five-year low on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2526785063","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526785063?lang=en_us&edition=fundamental","pubTime":"2025-04-10 09:57","pubTimestamp":1744250235,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Recce Pharmaceuticals slumps to five-year low on discounted placement ** Shares of Recce Pharmaceuticals RCE.AX fall 7.7% to A$0.300, their lowest levels since April 2, 2020** The pharmaceutical co announces a placement of A$5 million  and an entitlement offer of A$10.8 million to fund clinical trials in Indonesia and Australia** Issue price of A$0.28 for the placement represents a 13.8% discount to co's last close** Stock down ~38% YTD, including current session's moves  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nL3N3QO076:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2526322053","title":"BRIEF-Recce Pharmaceuticals Announces Placement And Entitlement Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526322053","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526322053?lang=en_us&edition=fundamental","pubTime":"2025-04-10 09:33","pubTimestamp":1744248814,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Announces Placement And Entitlement OfferApril 10  - Recce Pharmaceuticals Ltd RCE.AX:PLACEMENT AND ENTITLEMENT OFFER TO FUND PHASE III TRIALSA$5.0 MILLION PLACEMENT & A$10.8 MILLION ENTITLEMENT OFFERPLACEMENT AT A$0.28 PER NEW SHAREFurther company coverage: RCE.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250410:nTUEX9FFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2526232805","title":"Recce Pharmaceuticals Ltd-Cleansing Notice - Entitlement Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526232805","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526232805?lang=en_us&edition=fundamental","pubTime":"2025-04-10 07:55","pubTimestamp":1744242951,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nTUE5CTQR5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2526616328","title":"Recce Pharmaceuticals Ltd-Placement and Entitlement Offer to Fund Phase Iii Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2526616328","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526616328?lang=en_us&edition=fundamental","pubTime":"2025-04-10 07:44","pubTimestamp":1744242273,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nTUEX9FFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2526284353","title":"Recce Pharmaceuticals Ltd -  Placement at a$0.28 per New Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2526284353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526284353?lang=en_us&edition=fundamental","pubTime":"2025-04-10 07:44","pubTimestamp":1744242273,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250409:nTUEX9FFY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2517950397","title":"Further weakness as Recce Pharmaceuticals (ASX:RCE) drops 12% this week, taking three-year losses to 58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517950397","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517950397?lang=en_us&edition=fundamental","pubTime":"2025-03-05 07:37","pubTimestamp":1741131431,"startTime":"0","endTime":"0","summary":"The truth is that if you invest for long enough, you're going to end up with some losing stocks. But the long term...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rce/recce-pharmaceuticals-shares/news/further-weakness-as-recce-pharmaceuticals-asxrce-drops-12-th","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2514366902","title":"BUZZ-Australia's Recce Pharmaceuticals falls on widened loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2514366902","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514366902?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:40","pubTimestamp":1740706816,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Recce Pharmaceuticals falls on widened loss** Shares of Recce Pharmaceuticals RCE.AX fall 2.3% to A$0.420, their lowest since February 21, 2024** Pharmaceutical co posts HY net loss a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL3N3PJ04B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2514365716","title":"BRIEF-Recce Pharmaceuticals Says HY Net Loss For Period Attributable A$7.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514365716","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514365716?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:31","pubTimestamp":1740706295,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Says HY Net Loss For Period Attributable A$7.7 MillionFeb 28 (Reuters) - Recce Pharmaceuticals Ltd RCE.AX:HY NET LOSS FOR PERIOD ATTRIBUTABLE A$7.7 MILLIONFurther company coverage: RCE.AX ((Reuters.Briefs@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2BK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2514607068","title":"BRIEF-Recce Pharmaceuticals Says Japan Patent Allowance For Recce Anti-Infectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2514607068","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514607068?lang=en_us&edition=fundamental","pubTime":"2025-02-26 13:38","pubTimestamp":1740548287,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Says Japan Patent Allowance For Recce Anti-InfectivesFeb 26 (Reuters) - Recce Pharmaceuticals Ltd RCE.AX:JAPAN PATENT ALLOWANCE FOR RECCE ANTI-INFECTIVESFurther company coverage: RCE.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PG11F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2514071584","title":"Recce Pharmaceuticals Obtains Japan Patent for Anti-Infectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2514071584","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514071584?lang=en_us&edition=fundamental","pubTime":"2025-02-26 12:01","pubTimestamp":1740542472,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  received a notice of allowance from the Japan Patent Office for Patent Family 4 for its anti-infectives, according to a Wednesday filing with the Australian bourse.The claims relate to RECCE 327 and RECCE 529, which are both designed to treat bacterial and viral infections. The patent will expire in 2041.Recce Pharmaceuticals' shares were down past 2% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2514702382","title":"Recce Pharmaceuticals Ltd - Japan Patent Allowance for Recce Anti-Infectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2514702382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514702382?lang=en_us&edition=fundamental","pubTime":"2025-02-26 07:12","pubTimestamp":1740525172,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG11F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2512485681","title":"BRIEF-Recce Pharmaceuticals Reports Positive Data From Phase Ii Trial Of Recce® 327 Gel In Acute Bacterial Skin And Skin Structure Infections, Supporting Accelerated Commercialization Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2512485681","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512485681?lang=en_us&edition=fundamental","pubTime":"2025-02-19 23:03","pubTimestamp":1739977406,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Reports Positive Data From Phase Ii Trial Of Recce 327 Gel In Acute Bacterial Skin And Skin Structure Infections, Supporting Accelerated Commercialization PathwayFeb 19 (Re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA1WRNVK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2512101242","title":"Recce Pharmaceuticals Ltd - R327g Achieves 93% Primary Efficacy Endpoint in 14 Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2512101242","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512101242?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:00","pubTimestamp":1739970002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA1WRNVK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":62,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCE.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-04-15","symbol":"RCE.AU","defaultRemindTime":1744675200000,"type":"split","dateTimestamp":1744639200000,"forFactor":990476,"toFactor":1000000,"ratio":0.990476}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCE.AU\",market:\"AU\",,,undefined,":[]}}